Vimta Labs has completed the sale and transfer of its diagnostic and pathological services business as a going concern to Thyrocare Technologies on 11 October 2024. Powered by Capital Market - Live News

Net profit of Vimta Labs rose 0.66% to Rs 12.28 crore in the quarter ended June 2024 as against Rs 12.20 crore during the previous quarter ended June 2023. Sales declined 2.07% to Rs 81.76 crore in the quarter ended June 2024 as against Rs 83.49 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales81.7683.49 -2 OPM %29.9929.52 - PBDT24.7424.80 0 PBT16.5216.30 1 NP12.2812.20 1 Powered by Capital Market - Live News

Vimta Labs will hold a meeting of the Board of Directors of the Company on 17 July 2024.Powered by Capital Market - Live News

Vimta Labs announced that the 34th Annual General Meeting(AGM) of the company will be held on 18 July 2024.Powered by Capital Market - Live News

Net profit of Vimta Labs declined 2.60% to Rs 12.35 crore in the quarter ended March 2024 as against Rs 12.68 crore during the previous quarter ended March 2023. Sales declined 2.60% to Rs 79.69 crore in the quarter ended March 2024 as against Rs 81.82 crore during the previous quarter ended March 2023.For the full year,net profit declined 14.86% to Rs 41.01 crore in the year ended March 2024 as against Rs 48.17 crore during the previous year ended March 2023. Sales rose 0.02% to Rs 318.26 crore in the year ended March 2024 as against Rs 318.19 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales79.6981.82 -3 318.26318.19 0 OPM %30.6429.54 -27.2729.83 - PBDT24.3824.60 -1 88.6895.71 -7 PBT16.2816.55 -2 54.4865.00 -16 NP12.3512.68 -3 41.0148.17 -15 Powered by Capital Market - Live News